Semaglutide Side Effects: The Muscle-Loss Question, the Nausea, and What's Actually Serious

Does semaglutide cause muscle loss, especially in perimenopause?

Losing muscle along with fat isn't unique to semaglutide — it's a property of fast weight loss in general, and it shows up in placebo groups losing weight through diet alone too. In the body-composition sub-studies of semaglutide's own weight-management trials, most of the weight lost is fat, with roughly a quarter coming from lean tissue. That ratio isn't dramatically different from what dieting alone tends to produce.

What changes the stakes is timing. If you're in your 40s or already through the menopause transition, your muscle is losing ground to declining estrogen before semaglutide ever enters the picture — so a share of lean mass lost to the drug's effect lands on top of a deficit you're already running, rather than on a body with muscle to spare. That's the real reason this question gets asked so much more by women 40+ than by patients in their twenties on the same drug. For the research behind those numbers, whether semaglutide and tirzepatide differ, and what actually protects your muscle while you lose the weight, see GLP-1s and muscle loss in perimenopause, which goes deep on exactly this question rather than repeating it here.

What are the most common semaglutide side effects?

Semaglutide works by slowing digestion and turning down appetite signals in the brain, and nearly everything on the common side-effect list traces back to that one mechanism. Nausea leads by a wide margin — it showed up in about 44% of people on semaglutide in the trials behind Wegovy's approval, against 16% on placebo. Some form of gastrointestinal side effect touched about 73% of people on the drug overall, against 47% on placebo — a wide gap, though most of it stayed mild to moderate rather than severe. The rest of the GI list — vomiting, diarrhea, constipation — breaks down below.

• Nausea — the leading complaint across every trial, usually strongest right after each dose increase
• Vomiting — reported by about 25% on semaglutide vs. 6% on placebo, less common than nausea and more likely early in treatment
• Diarrhea — about 30% on semaglutide vs. 16% on placebo
• Constipation — sometimes alternating with diarrhea, at different points
• Bloating, abdominal pain, or reflux
• Fatigue, headache, or mild dizziness, particularly if food intake drops sharply
• Injection-site redness or irritation, for the injectable form

None of this signals something gone wrong. It's the expected pharmacology of the drug doing its job — and it's exactly why the dosing schedule climbs gradually instead of starting at a maintenance dose.

How to relieve nausea from semaglutide

A handful of practical habits cover most of what shows up in the first weeks after each dose step, without requiring you to just push through it.

• Respect the titration pace — each dose increase is spaced out specifically to give your gut time to adjust, and asking to move faster tends to backfire; slowing the pace down is a fair thing to raise with your prescriber if nausea is rough
• Go smaller and lower-fat with meals — semaglutide already slows how fast your stomach empties, and a large or fatty meal on top of that is the most common nausea trigger
• Stay ahead of hydration, especially during a rough stretch of vomiting or diarrhea — dehydration compounds nausea and raises the risk of the more serious complications below
• Watch your injection timing — some people do better dosing at a specific time of day or day of the week once they notice when nausea tends to peak

Does semaglutide cause hair loss?

There's no established mechanism by which semaglutide acts on hair follicles directly. What shows up in some people instead is telogen effluvium — a temporary, diffuse shedding pattern triggered by fast weight loss itself, whatever caused it. In semaglutide's STEP 1 trial, alopecia was reported more often on the drug than on placebo, and the rate climbed further among the subset of people who lost more than a fifth of their body weight. Shedding tracking the amount of weight lost, rather than the drug itself, is consistent with telogen effluvium rather than a direct drug effect.

The timing is fairly predictable: shedding tends to start a few months after the weight loss itself, not right after starting the medication, and most people find it resolves as weight stabilizes. If you're already noticing perimenopausal thinning on top of this, the same telogen-effluvium mechanism is worth understanding on its own terms — see perimenopause hair loss for the fuller mechanism, the difference from pattern hair loss, and what actually helps.

Is semaglutide safe?

For most people, yes. Semaglutide has one of the longer track records in this drug class — it's been prescribed for type 2 diabetes since 2017, and the weight-management dose behind Wegovy has its own large randomized trials, including the SELECT cardiovascular outcomes trial, which found a reduced rate of major cardiovascular events in adults with existing cardiovascular disease and overweight or obesity. The common side effects above are frequent but usually manageable, and the genuinely serious risks are uncommon.

One distinction worth naming plainly: Ozempic is FDA-approved for type 2 diabetes, not weight loss — using it for weight management without a diabetes diagnosis is off-label use of the same molecule at a lower dose. Wegovy carries the specific chronic weight-management approval. It's the same active ingredient studied at similar doses either way, but insurance coverage and the FDA's own review don't automatically extend from one indication to the other.

One more question worth addressing directly, since it circulated widely: after postmarketing reports raised concerns about a link to suicidal thoughts, the FDA reviewed clinical trial and safety data across the GLP-1 class, including a large meta-analysis and a healthcare-claims comparison. The agency's conclusion, published in early 2026, found no increased risk of suicidal ideation or behavior tied to this drug class, and the FDA has asked manufacturers to remove that warning language from labeling.

Does semaglutide cause cancer?

Semaglutide carries a boxed warning — the FDA's most serious label warning — about thyroid C-cell tumors, based on rodent studies where the drug caused these tumors in mice and rats at clinically relevant exposures over their lifetimes. Whether that translates to humans isn't established: no confirmed case of semaglutide causing thyroid C-cell cancer has been reported in people, and the warning doesn't apply to the common thyroid cancers that make up the vast majority of real-world diagnoses. It does mean semaglutide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and prescribers are asked to counsel patients on the specific symptoms worth reporting: a neck lump, persistent hoarseness, or trouble swallowing.

Pancreatic cancer had a murkier research history for years, starting with an early observational signal in 2011. The more recent picture is reassuring rather than alarming: a meta-analysis of randomized trials published in mid-2026, covering more than 1.6 million patients, found GLP-1 drugs including semaglutide associated with a lower rate of pancreatic cancer than several other diabetes medications — not a higher one. That's not a lifetime guarantee, and cancer research at this scale keeps accumulating, but it's a meaningfully different picture than the uncertainty that lingered a few years ago.

What are the long-term side effects of semaglutide?

Semaglutide's longest track record comes from its original population — people with type 2 diabetes, followed for years. What's newer is the scale of weight-management use, often at higher doses and for longer stretches than those original diabetes trials studied most closely. A few questions are still genuinely being worked through: how years of sustained rapid weight loss affect bone density and muscle mass, whether the rodent-based thyroid signal holds any relevance as more years of human exposure accumulate, and what happens metabolically for people who eventually stop the medication after using it for weight management rather than diabetes control. On that last point, the STEP 1 trial's extension found that participants who discontinued semaglutide regained a substantial share of their lost weight within a year, with metabolic markers moving back in the same direction — a real finding, not a hidden one, and part of why most clinicians frame this as a long-term treatment rather than a short course.

How long do semaglutide side effects last?

Most of the GI symptoms follow a fairly predictable arc: they tend to spike in the days right after each dose increase, then settle over the following one to two weeks as your body adjusts to that step, before the next increase starts the cycle again. By the time you reach a maintenance dose and the titration stops, most people find the nausea and stomach upset have largely faded into the background. Hair shedding, when it happens, runs on a slower and separate timeline — starting a few months into meaningful weight loss and typically resolving over the following several months once your weight stabilizes.

Which side effects need same-day medical attention?

The everyday nausea-and-bloating cluster above is one category. This is a different one — specific symptoms that overlap with the serious risks and shouldn't wait for a routine follow-up message. In Wegovy's own trials, gallstones and gallbladder inflammation showed up more often on the drug than on placebo, and confirmed pancreatitis was rare on either side but more common on semaglutide — part of why severe abdominal pain that radiates to your back gets taken seriously rather than written off as ordinary GI upset.

• Severe, persistent abdominal pain, especially if it radiates to your back, with or without vomiting — a possible sign of pancreatitis
• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes — possible gallbladder involvement
• A new lump or swelling in your neck, persistent hoarseness, or trouble swallowing — the symptoms the FDA specifically asks prescribers to counsel patients on, given the thyroid warning
• Signs of severe dehydration — very reduced urination, dizziness on standing, confusion — especially after several days of vomiting or diarrhea
• Signs of severe low blood sugar if you also take insulin or a sulfonylurea for diabetes — shakiness, confusion, sweating that doesn't resolve with food

Any one of those is worth a same-day call to your prescriber or urgent care, not a message that can wait until morning.

Compounded vs. brand semaglutide: does the source change your side-effect risk?

Most of the providers on this page's table dispense compounded semaglutide — a version mixed by a licensed pharmacy rather than the finished, FDA-approved product Novo Nordisk manufactures as Wegovy or Ozempic. That distinction matters specifically for side effects, not just legality. A compounded product can be chemically the same active peptide, but the finished batch hasn't gone through the FDA's premarket manufacturing review, and quality control varies by which pharmacy actually fills your prescription.

The clearest evidence of that variance: the FDA had logged more than 500 adverse-event reports tied to compounded semaglutide by mid-2025, a meaningful share involving dosing errors — patients or providers miscalculating how much to draw from a multidose vial, sometimes ending up with several times the intended dose. Reported overdose effects included the same GI symptoms as ordinary side effects, but more severe, along with dehydration, fainting, and in some cases pancreatitis or gallstones requiring hospitalization. Most of that risk traces back to unlabeled or confusingly labeled vials and patients new to self-injection, not the compounded peptide itself being inherently more dangerous — but it's a real, documented category of risk that doesn't exist with a pre-filled, clearly labeled brand-name pen.

What remains legal in mid-2026 is 503A compounding — a state-licensed pharmacy mixing medication for an individual, named patient under a valid prescription. The FDA proposed in April 2026 to remove semaglutide from the separate 503B bulk-compounding list entirely; that proposal's public comment period closed in June 2026, and no final rule had been issued as of this writing. Every compounded provider on this page operates through the 503A pathway. Before enrolling anywhere, it's reasonable to ask which specific pharmacy fills your prescription and to request a Certificate of Analysis for the batch — a legitimate 503A program will have a straightforward answer. If you're specifically on Ozempic rather than a semaglutide compound, see Ozempic's side-effect breakdown for the same distinction applied to that product, or the broader GLP-1 side-effect guide if you're weighing semaglutide against tirzepatide too.

Choosing where to start, with side effects in mind

If a side effect is part of what you're weighing before you start — or you're already on semaglutide and want to know what changing course actually costs — the real differences between providers show up in whether the price moves when your dose does, whether labs are included, and whether switching formulation costs you a second bill.

Mochi Health keeps its $99/mo medication price flat at every dose, so a slower titration to ease nausea, or a switch between injection, oral tablet, drops, or microdose, doesn't change your bill — the $79/mo membership is the separate cost to track. ABOM-certified physicians review your case, though labs aren't bundled in.

Henry Meds bundles everything into one flat price with no separate membership — oral runs $249/mo, injection $297/mo — so moving from injection to the tablet if nausea or injection-site irritation is the issue costs exactly the same. Fridays leans the other direction: dietitian access and group coaching are part of the price, useful if appetite changes or nausea are what you're managing day to day, though the cheapest rate requires a year upfront and its BBB file shows real refund complaints worth reading first.

Willow charges a flat $299/mo at any dose in its roughly 33 supported states, which similarly protects you from a price hike if you and your provider decide to slow the titration down. Hers shifted away from compounded semaglutide as its default offer in March 2026, so most new patients are now getting brand-name Wegovy — meaning the side-effect profile matches the FDA label directly rather than depending on which compounding pharmacy filled the order, at the cost of a membership fee billed separately from the medication. For the brand pathway without a telehealth membership at all, NovoCare's own self-pay program runs from a time-limited introductory rate up to $349–$399/mo ongoing, or a flat $499/mo direct option at any dose.